TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28254158
Drug: Motivational Enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational Enhancement Therapy (MET)
Study: 18537952
Drug: Sildenafil (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (initial dose 50 mg, adjustable to 25 or 100 mg)
Study: 18537952
Drug: Apomorphine (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine (initial dose 2 mg, adjustable to 3 mg)
Study: 18537952
Drug: Preference after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preference after treatment
Study: 12556143
Drug: 6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg artemether, administered orally for a total of six doses once every 4 weeks
Study: 12556143
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered orally for a total of six doses once every 4 weeks
Study: 12556143
Drug: 6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg artemether
Study: 10659911
Drug: Estroprogestin (E/P)
Normalized name: E.P.O.
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estroprogestin (E/P) pill (gestroden 0.75 mg and ethynlestradiol 0.03 mg) for 12 months
Study: 10659911
Drug: Gonadotrophin releasing
Normalized name: Gonadotrophin releasing factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotrophin releasing hormone agonist (GNRHa) (tryptorelin 3.75 mg slow release every 28 days for 4 months) followed by E/P pill for 8 months
Study: 29869298
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg TQ Intermediate Aged
Study: 28404841
Drug: Modafinil 200
Normalized name: modafinil 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil 200 mg daily for 6 weeks
Study: 9484423
Drug: Modafinil 200
Normalized name: modafinil 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil 200 mg daily
Study: 25099747
Drug: Symbiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symbiotic therapy (Group A)
Study: 22057309
Drug: Fentanyl 1.5
Normalized name: fentanyl 1.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 1.5 μg/kg before induction, additional 50-μg boluses during anesthesia
Study: 22057309
Drug: Remifentanil 1
Normalized name: remifentanil 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 1 μg/kg infused in 10 min before induction, 0.1 μg/kg/min during anesthesia
Study: 22057309
Drug: Dexmedetomidine 1
Normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1 μg/kg infused in 10 min before induction, 1 μg/kg/h during anesthesia
Study: 11078175
Drug: Indomethacin 50
Normalized name: indomethacin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 50 mg twice daily for 3 weeks
Study: 9187896
Drug: Indigenous material
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indigenous material graft (rectal fascia)
Study: 2412002
Drug: Dextran at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextran at 1 g/kg wt/24 hr for 5 days in addition to standard resuscitation and treatment
Study: 29343142
Drug: abobotulinumtoxinA, 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: abobotulinumtoxinA, 500 U/2 mL dilution
Study: 10816223
Drug: Local administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local administration of immunoglobulin G (IgG) intranasally daily for 6 months
Study: 10816223
Drug: Placebo intranasally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intranasally daily for 6 months
Study: 10816223
Drug: Local administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local administration of immunoglobulin G (IgG)
Study: 8866410
Drug: rhuEPO treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhuEPO treatment for 1 year (Group A)
Study: 8866410
Drug: rhuEPO treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhuEPO treatment for 2 years (Group B)
Study: 8866410
Drug: rhuEPO treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhuEPO treatment (both groups)
Study: 24913337
Drug: Adaptive Pacing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptive Pacing Therapy (APT)
Study: 8870441
Drug: Finasteride 5
Normalized name: finasteride 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride 5 mg/day
Study: 30521699
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment according to national guidance
Study: 19343062
Drug: Bifendate (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifendate (three times daily for 14 days)
Study: 15325876
Drug: TSP/HEPA cleaning
Approvals — FDA: no, EMA: no, PMDA: no
Description: TSP/HEPA cleaning method (high-efficiency particulate air vacuum cleaner and tri-sodium phosphate solution)
Study: 11174679
Drug: Mandibular implant-supported
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular implant-supported overdenture (IOD)
Study: 9436823
Drug: celiprolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: celiprolol (200 mg)
Study: 9436823
Drug: celiprolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: celiprolol (200 mg and 800 mg) with atenolol
Study: 27470233
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (bolus + 48-hr infusion)
Study: 27470233
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical infusion volume and duration)
Study: 26703889
Drug: Everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 10 mg per day
Study: 8673750
Drug: Salt supplement
Normalized name: Sodium Chloride 454 mg / Potassium Chloride 30 mg ORAL TABLET [Thermotabs Buffered Salt Supplement]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salt supplement (120 mmol/day of sodium chloride)
Study: 1496946
Drug: Iron therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron therapy (syrup containing iron, daily for 2 months)
Study: 8105519
Drug: Inhaled terbutaline
Normalized name: terbutaline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled terbutaline
Study: 9259905
Drug: Oral terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terbutaline
Study: 11691705
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate (5 to 200 mg/day)
Study: 7956700
Drug: Lymphokine activated
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphokine activated killer (LAK) cell therapy
Study: 24849450
Drug: Dexmedetomidine 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.8 µg·kg(‐1)·h(‐1) maintenance dose
Study: 22929629
Drug: 25 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 μg intravaginal Misoprostol
Study: 20089970
Drug: Monoclonal antibodies
Normalized name: Monoclonal antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibodies (CDA1 and CDB1) at a dose of 10 mg/kg
Study: 10354248
Drug: Management of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Management of patients with cataract attending a peripheral ophthalmic clinic for day-surgery
Study: 7669489
Drug: Zidovudine (ZDV)
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine (ZDV) 200 mg m‐2
Study: 7669489
Drug: Dideoxyinosine (ddI)
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dideoxyinosine (ddI) 100 mg m‐2
Study: 7669489
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ZDV 200 mg m‐2 plus ddI 100 mg m‐2
Study: 7379451
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal (50 gm as a water suspension followed by 4 doses of 17 gm at 12-hr intervals)
Study: 31411383
Drug: Orodispersible minitablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orodispersible minitablet (ODMT) 10 x 1 mg swallowed with water
Study: 31411383
Drug: Reference product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference product (RP) Renitec, 2 x 5 mg tablets swallowed with water
Study: 18936284
Drug: Taranabant 6
Normalized name: Taranabant
DrugBank: Taranabant (DB06624)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taranabant 6 mg/day
Study: 11179527
Drug: Single-dose of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose of amiodarone (three 200-mg Cordarone tablets) after an overnight fast
Study: 11179527
Drug: Single-dose of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose of amiodarone (three 200-mg Cordarone tablets) after a standard high-fat breakfast
Study: 9530364
Drug: Granisetron (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (40 micrograms/kg) infused for 30 minutes before CDDP infusion (standard method)
Study: 21203878
Drug: 0.75% hyperbaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% hyperbaric bupivacaine 7.5 mg
Study: 21203878
Drug: 2% preservative-free
Normalized name: lidocaine 2% preservative-free injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% preservative-free 2-chloroprocaine 40 mg
Study: 18471639
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL of gatifloxacin in the dilating mixture
Study: 18471639
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL of moxifloxacin in the dilating mixture
Study: 17171602
Drug: Interpersonal and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpersonal and Social Rhythm Therapy
Study: 14623834
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg oral dexketoprofen trometamol
Study: 8442438
Drug: Intermittent, cyclic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent, cyclic etidronate (400 mg/day for 2 weeks followed by 13 weeks free from study drug administration)
Study: 3801827
Drug: No special
Approvals — FDA: no, EMA: no, PMDA: no
Description: No special treatment post-operatively (Control)
Study: 27621610
Drug: Aclidinium/formoterol 400/12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aclidinium/formoterol 400/12 µg
Study: 28918877
Drug: Raltegravir 400
Normalized name: raltegravir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir 400 mg twice daily with tenofovir disoproxil fumarate and emtricitabine
Study: 28918877
Drug: Raltegravir 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir 1200 mg once daily
Study: 19782784
Drug: Formal exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formal exercise program in addition to optimal medical therapy
Study: 11686543
Drug: Enalapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5 mg/day)
Study: 6359471
Drug: Calcitonin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitonin treatment for four weeks
Study: 6359471
Drug: Calcitonin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitonin treatment for over one year
Study: 6359471
Drug: Calcitonin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitonin treatment after discontinuation
Study: 4011138
Drug: Hypotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypotonic saline solution (150 mOsm/L)
Study: 12950328
Drug: Transdermal oestrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal oestrogen replacement therapy
Study: 1442656
Drug: 50-mg/d iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50-mg/d iron supplement and a low food-iron diet (50 FE + EX)
Study: 1442656
Drug: Meat supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meat supplement and high food-iron diet (M + EX)
Study: 6535823
Drug: Medial epicondylectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medial epicondylectomy and external decompression with steroid therapy
Study: 25177431
Drug: Steroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid therapy alone
Study: 31208376
Drug: Smartphone app
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Smartphone app and TAU (treatment as usual)
Study: 24768633
Drug: Subcutaneous (SQ)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SQ) injection of anthrax vaccine adsorbed (AVA)
Study: 24768633
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) injection of anthrax vaccine adsorbed (AVA)
Study: 24768633
Drug: Subcutaneous (SQ)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SQ) injection of anthrax vaccine adsorbed (AVA) in obese participants
Study: 2859047
Drug: Atenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (100 mg)
Study: 10226853
Drug: Transdermal NTG
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal NTG (0.6 mg/h)
Study: 10226853
Drug: Sublingual NTG
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual NTG after 5 days of sustained transdermal NTG therapy (0.6 mg/h)
Study: 10226853
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin C (2 g)
Study: 1860385
Drug: L-tryptophan 3.0g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-tryptophan 3.0g/day for six weeks
Study: 6617066
Drug: Amiloride (median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride (median dosage 15 mg/day or 5 mg per 25 mg hydrochlorothiazide)
Study: 6617066
Drug: Hydrochlorothiazide (continued
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (continued therapy)
Study: 6617066
Drug: Amiloride (adjunctive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride (adjunctive treatment)
Study: 28484877
Drug: Two NSAIDs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two NSAIDs (diclofenac and celecoxib) with morphine sulfate 10 mg/12 h
Study: 28484877
Drug: Diclofenac with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac with morphine sulfate 10 mg/12 h
Study: 26388272
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg IV midazolam (Group III)
Study: 21127883
Drug: Intravenous glutathione
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glutathione (GSH) 100 mg/min for 30 min before CAG
Study: 21127883
Drug: Intravenous glutathione
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glutathione (GSH)
Study: 19843054
Drug: HP‐beta‐CD formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP‐beta‐CD formulation at 1, 10, 30 microg
Study: 19843054
Drug: HP‐beta‐CD formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP‐beta‐CD formulation at 100 microg
Study: 19843054
Drug: Tween formulation
Normalized name: Tween 80
DrugBank: Polysorbate 80 (DB11063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tween formulation at 100 microg
Study: 17928994
Drug: Strict glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strict glucose control group (SGC) with a blood glucose target of 4-6 mmol/l
Study: 10806134
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 mg)
Study: 8488960
Drug: 0.015-0.025 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.015-0.025 mg/kg haloperidol
Study: 29083331
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml normal saline (control)
Study: 3318435
Drug: Nabumetone (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabumetone (1,000 mg at bedtime)
Study: 1092727
Drug: Naproxen (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (250 mg twice daily)
Study: 25887136
Drug: BT086 (IgM-enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: BT086 (IgM-enriched immunoglobulin preparation)
Study: 21586215
Drug: Adaptive oral
Normalized name: ADAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptive oral hygiene devices and orofacial exercise
Study: 7750407
Drug: Mifepristone 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 25 mg b.i.d. (total amount of 125mg) + PG05 1mg in the morning of the 3rd day
Study: 7750407
Drug: Mifepristone 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 50 mg immediately, then 25 mg b.i.d. (total amount of 150mg) + misoprostol 600 micrograms
Study: 7750407
Drug: Mifepristone 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 50 mg in the morning and 25mg in the evening for two days (total amount of 150 mg) + misoprostol 600 micrograms
Study: 7750407
Drug: Mifepristone 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 25 mg b.i.d. (total amount of 125mg) + misoprostol 400 micrograms
Study: 30957736
Drug: Present-Centred Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Present-Centred Therapy (PCT)
Study: 15013268
Drug: Clopidogrel pretreatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel pretreatment (300 mg loading dose 24 hours before PCI)
Study: 10374272
Drug: Nitrendipine treatment
Normalized name: nitrendipine
DrugBank: Nitrendipine (DB01054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine treatment group
Study: 7939508
Drug: Standard CPB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard CPB circuit with a standard heparin dose (300 IU/kg)
Study: 3064861
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) administered to 188 patients
Study: 14699304
Drug: Alendronate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (10 mg) and 600 mg calcium per day for 2 years
Study: 14699304
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and 600 mg calcium per day for 2 years
Study: 8837183
Drug: Spinal Anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal Anesthesia (SA) with 3 mL of hyperbaric 0.5% bupivacaine
Study: 12531808
Drug: Irradiation plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irradiation plus G-CSF
Study: 12531808
Drug: Neither irradiation
Normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neither irradiation nor G-CSF
Study: 8969721
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate infusion, 25 mg/kg (maximum, 2 gm) for 20 minutes
Study: 8443401
Drug: Aminoglutethimide (Ag)
Normalized name: Aminoglutethimide
DrugBank: Aminoglutethimide (DB00357)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminoglutethimide (Ag) 500 mg/day with hydrocortisone supplementation from 30 to 60 mg/day
Study: 8443401
Drug: Oral medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral medroxyprogesterone acetate (MPA) 500 mg twice a day
Study: 15891564
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy
Study: 6391658
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy plus immunotherapy with PSK
Study: 31241761
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (live implant insertions)
Study: 27718784
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (methotrexate, docetaxel, or cetuximab)
Study: 22238398
Drug: Intraduodenal infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal infusions of glucose at 1, 2, or 3 kcal/min for 60 minutes
Study: 19962342
Drug: Ribavirin plus
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin plus supportive treatment (Group A, n=64)
Study: 19962342
Drug: Supportive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive treatment only (Group B, n=72)
Study: 16298651
Drug: No antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibody induction (group 3)
Study: 16298651
Drug: Daclizumab 1
Normalized name: daclizumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab 1 mg/kg/dose every 14 days for 5 doses (group 1)
Study: 16298651
Drug: Daclizumab 2
Normalized name: daclizumab 25 MG per 5 ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab 2 mg/kg/dose for 2 doses (group 2)
Study: 21607554
Drug: Single-agent docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-agent docetaxel
Study: 12065558
Drug: Docetaxel 100
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 100 mg/m² on day 1
Study: 7611158
Drug: Nicotinic acid
Normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinic acid (1.2 g/day) and lovastatin (20 mg/day)
Study: 10362210
Drug: Lovastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (20 mg/day)
Study: 7611158
Drug: Nicotinic acid
Normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinic acid (1.2 g/day)
Study: 7611158
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nicotinic acid and lovastatin
Study: 16911626
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine twice daily at breakfast and dinner
Study: 16911626
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine once daily at dinner time
Study: 9010943
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch of identical size.
Study: 9010943
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl patch (50-75 micrograms/h).
Study: 9010943
Drug: Ketorolac (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac (60 mg intramuscularly) administered approximately 20-30 minutes before expected end of surgery.
Study: 9010943
Drug: Acetaminophen (1,300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (1,300 mg) administered between ketorolac doses if pain persisted.